These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

661 related articles for article (PubMed ID: 28655025)

  • 1. Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder: A Randomized Clinical Trial.
    Walsh SL; Comer SD; Lofwall MR; Vince B; Levy-Cooperman N; Kelsh D; Coe MA; Jones JD; Nuzzo PA; Tiberg F; Sheldon B; Kim S
    JAMA Psychiatry; 2017 Sep; 74(9):894-902. PubMed ID: 28655025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic-pharmacodynamic analysis of drug liking blockade by buprenorphine subcutaneous depot (CAM2038) in participants with opioid use disorder.
    Walsh SL; Comer SD; Zdovc JA; Sarr C; Björnsson M; Strandgården K; Hjelmström P; Tiberg F
    Neuropsychopharmacology; 2024 May; 49(6):1050-1057. PubMed ID: 38200140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal.
    D'Onofrio G; Herring AA; Perrone J; Hawk K; Samuels EA; Cowan E; Anderson E; McCormack R; Huntley K; Owens P; Martel S; Schactman M; Lofwall MR; Walsh SL; Dziura J; Fiellin DA
    JAMA Netw Open; 2024 Jul; 7(7):e2420702. PubMed ID: 38976265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of a buprenorphine subcutaneous depot formulation (CAM2038) for once-weekly dosing in patients with opioid use disorder.
    Haasen C; Linden M; Tiberg F
    J Subst Abuse Treat; 2017 Jul; 78():22-29. PubMed ID: 28554599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic Evaluation of Once-Weekly and Once-Monthly Buprenorphine Subcutaneous Injection Depots (CAM2038) Versus Intravenous and Sublingual Buprenorphine in Healthy Volunteers Under Naltrexone Blockade: An Open-Label Phase 1 Study.
    Albayaty M; Linden M; Olsson H; Johnsson M; Strandgården K; Tiberg F
    Adv Ther; 2017 Feb; 34(2):560-575. PubMed ID: 28070862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder.
    Frost M; Bailey GL; Lintzeris N; Strang J; Dunlop A; Nunes EV; Jansen JB; Frey LC; Weber B; Haber P; Oosman S; Kim S; Tiberg F
    Addiction; 2019 Aug; 114(8):1416-1426. PubMed ID: 31013390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population Pharmacokinetic Analysis Supports Initiation Treatment and Bridging from Sublingual Buprenorphine to Subcutaneous Administration of a Buprenorphine Depot (CAM2038) in the Treatment of Opioid Use Disorder.
    Björnsson M; Acharya C; Strandgården K; Tiberg F
    Clin Pharmacokinet; 2023 Oct; 62(10):1427-1443. PubMed ID: 37584841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
    Dunn KE; Tompkins DA; Bigelow GE; Strain EC
    JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended-Release Injection vs Sublingual Buprenorphine for Opioid Use Disorder With Fentanyl Use: A Post Hoc Analysis of a Randomized Clinical Trial.
    Nunes EV; Comer SD; Lofwall MR; Walsh SL; Peterson S; Tiberg F; Hjelmstrom P; Budilovsky-Kelley NR
    JAMA Netw Open; 2024 Jun; 7(6):e2417377. PubMed ID: 38916892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of an injection depot formulation of buprenorphine: placebo comparison.
    Sigmon SC; Wong CJ; Chausmer AL; Liebson IA; Bigelow GE
    Addiction; 2004 Nov; 99(11):1439-49. PubMed ID: 15500597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder: A Randomized Clinical Trial.
    Lofwall MR; Walsh SL; Nunes EV; Bailey GL; Sigmon SC; Kampman KM; Frost M; Tiberg F; Linden M; Sheldon B; Oosman S; Peterson S; Chen M; Kim S
    JAMA Intern Med; 2018 Jun; 178(6):764-773. PubMed ID: 29799968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period.
    Correia CJ; Walsh SL; Bigelow GE; Strain EC
    Psychopharmacology (Berl); 2006 Dec; 189(3):297-306. PubMed ID: 17013637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial.
    Lintzeris N; Dunlop AJ; Haber PS; Lubman DI; Graham R; Hutchinson S; Arunogiri S; Hayes V; Hjelmström P; Svedberg A; Peterson S; Tiberg F
    JAMA Netw Open; 2021 May; 4(5):e219041. PubMed ID: 33970256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Haight BR; Learned SM; Laffont CM; Fudala PJ; Zhao Y; Garofalo AS; Greenwald MK; Nadipelli VR; Ling W; Heidbreder C;
    Lancet; 2019 Feb; 393(10173):778-790. PubMed ID: 30792007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between opioid cross-tolerance during buprenorphine stabilization and return to opioid use during buprenorphine dose tapering.
    Greenwald MK; Sogbesan T; Moses TEH
    Psychopharmacology (Berl); 2024 Jun; 241(6):1151-1160. PubMed ID: 38326506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of opioid dependence with depot buprenorphine (CAM2038) in custodial settings.
    Dunlop AJ; White B; Roberts J; Cretikos M; Attalla D; Ling R; Searles A; Mackson J; Doyle MF; McEntyre E; Attia J; Oldmeadow C; Howard MV; Murrell T; Haber PS; Lintzeris N
    Addiction; 2022 Feb; 117(2):382-391. PubMed ID: 34184798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid Initiation of Injection Naltrexone for Opioid Use Disorder: A Stepped-Wedge Cluster Randomized Clinical Trial.
    Shulman M; Greiner MG; Tafessu HM; Opara O; Ohrtman K; Potter K; Hefner K; Jelstrom E; Rosenthal RN; Wenzel K; Fishman M; Rotrosen J; Ghitza UE; Nunes EV; Bisaga A
    JAMA Netw Open; 2024 May; 7(5):e249744. PubMed ID: 38717773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained-Release Buprenorphine (RBP-6000) Blocks the Effects of Opioid Challenge With Hydromorphone in Subjects With Opioid Use Disorder.
    Nasser AF; Greenwald MK; Vince B; Fudala PJ; Twumasi-Ankrah P; Liu Y; Jones JP; Heidbreder C
    J Clin Psychopharmacol; 2016 Feb; 36(1):18-26. PubMed ID: 26650971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained release d-amphetamine reduces cocaine but not 'speedball'-seeking in buprenorphine-maintained volunteers: a test of dual-agonist pharmacotherapy for cocaine/heroin polydrug abusers.
    Greenwald MK; Lundahl LH; Steinmiller CL
    Neuropsychopharmacology; 2010 Dec; 35(13):2624-37. PubMed ID: 20881947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of pioglitazone and proinflammatory cytokines during buprenorphine taper in patients with opioid use disorder.
    Schroeder JR; Phillips KA; Epstein DH; Jobes ML; Furnari MA; Kennedy AP; Heilig M; Preston KL
    Psychopharmacology (Berl); 2018 Oct; 235(10):2957-2966. PubMed ID: 30079432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.